Solr Search

alled tau—a common culprit in a number of neurodegenerative diseases—we make the case that focused strategic investment in tau research and the , At present, no disease-modifying therapies for the pure tauopathies exist. Researchers are working to develop effective therapeutic agents, which include approaches such as decreasing the amount of tau within the brain., Symptomatic Interventions At present, no disease-modifying therapies for the pure tauopathies exist.

ers such as product developers and regulators to define and implement the “how to” of patient

ilities and broader commercialization ecosystems that contribute to firm expansion, high-skills job creation, and broad economic growth.

ephen Hahn, Commissioner, US Food and Drug Administration, followed by a panel discussion.

S Department of Education Moderator Ian Rowe, Resident Fellow, AEI